Drugs / Mitoguazone
Mitoguazone
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT00002348 | — | HIV infectious disease, non-Hodgkin lymphoma | Genzyme, a Sanofi Company | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT00920153 | May 2008 → Mar 2016 | lymphoma | French Innovative Leukemia Organisation | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Mitoguazone | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00002348 ↗ |
| Known as | MGBG | “To estimate the response rate, response duration, clinical benefit, and toxicity of mitoguazone dihydrochloride (MGBG) in patients with AIDS-related refractory or relapsing...” NCT00002348 ↗ |
| Known as | Mitoguazona | ChEMBL registry synonym — accepted as the source's own label CHEMBL216913 ↗ |
| Known as | mitoguazone dihydrochloride | “To estimate the response rate, response duration, clinical benefit, and toxicity of mitoguazone dihydrochloride (MGBG) in patients with AIDS-related refractory or relapsing...” NCT00002348 ↗ |
| Modality | Small molecule | — CHEMBL216913 ↗ |